Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535307 | 1.00 | NFE2L2 (0.56) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL9454729 | 1.00 | NFE2L2 (0.56) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL1901796 | 0.82 | NFE2L2 (0.68) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL1901794 | 0.82 | NFE2L2 (0.68) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL611291 | 0.79 | CNR2 (0.42) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL611292 | 0.79 | CNR2 (0.42) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL421797 | 0.77 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL421796 | 0.77 | MAOB (0.56) | NFE2L2MAOBCYP19A1MAOARELA | |
| (Z)-1,2-Diphenylethene SCHEMBL28156521 | 0.76 | MAOB (0.65) | NFE2L2MAOBCYP19A1MAOARELA | |
| (Z)-1,2-Diphenylethene SCHEMBL27412567 | 0.76 | MAOB (0.65) | NFE2L2MAOBCYP19A1MAOARELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592130-B1 | PHOTOCHROMIC MATERIAL | MITSUBISHI GAS CHEMICAL CO (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8748629-B2 | Photochromic material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2014-06-10 | — | — | US | disclosed |
| EP-2592130-A1 | PHOTOCHROMIC MATERIAL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130102775-A1 | PHOTOCHROMIC MATERIAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NFE2L2 846/4885MAOB 2140/4885CYP19A1 3120/4885 |
| US-20130102775-A1 | PHOTOCHROMIC MATERIAL | RB1, BRD4, H1-4 | NFE2L2 827/4885MAOB 1334/4885CYP19A1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.